Phosphagenics

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). Phosphagenics' ADR's (PPGNY) are traded on the OTCQX in the US.



	Transdermal diclofenac enters phase 1 clinical trial in humans 12 November 2008 Phosphagenics Limited announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac. To view the release in full please click here.
	Metabolic Syndrome Phase 2 Clinical Trial Recruitment Completed 05 November 2008 Phosphagenics Limited today announced that recruitment of the Phospha E® phase 2 clinical trial for the management of metabolic syndrome has been completed. Five sites throughout Australia were used to recruit 160 patients for the efficacy trial. To view the release in full please click here.

Web Site Design & Business Hosting by Simple I.D.